July 1, 2018
Obtained pre-A round of investment from 'National Venture Capital', 'Xiangshang Investment', 'Jiangmen Taikang' and other institutions
Congratulations to QuaCell Biotechnology for completing the pre-A round of financing, which will be used for drug research and development, medium and other innovative research of pharmaceutical technology, as well as improving the company's ownership structure. This round of financing was completed with tens of millions of investment from Guangdong National Innovation Investment Management Co., Ltd. ("National Venture Capital"), Zhongshan Xiangshang Investment Management Co., Ltd. ("Xiangshang Investment")and Jiangmen Taikang Investment Partnership Co., Ltd. ("Jiangmen Taikang").
Quacell Biotechnology, Co., Ltd., headquartered in Zhongshan City, Guangdong-Hong Kong-Macao Greater Bay Area, is a rapidly growing global biotechnology company. At present, the company has about 7000 square meters of modern biomedical innovation service platform, which covers culture medium development and production, cell line development to GMP pilot production.
Quacell adheres to ISO and GMP regulations and focuses on the research and manufacturing of cell culture medium, providing key raw materials for global biopharmaceutical and gene therapy enterprises. Focusing on customer requirements, it provides integrated services from DNA to GMP production following FDA/NMPA requirements and has won the recognition and trust of nearly 100 domestic and foreign biopharmaceutical and biotechnology enterprises.
Since its establishment, the company has obtained strategic investment from many well-known venture capital funds in the industry, including Shenzhen Capital Group CO., and National Venture Capital, and other institutions, and won many awards, including Pearl River Entrepreneurial Talent Enterprise, National Winning Project Enterprise of China Innovation and Entrepreneurship Competition, Top 50 "Potential Enterprises" of Guangdong-Hong Kong-Macao Greater Bay Area, and the Most Potential Leading Enterprise in Asia. The company is committed to becoming a global leader in industrial cell culture applications.
Dr. Poon, CEO of QuaCell Biotechnology, Co., Ltd. was honored to be elected Associate Editor of RE: GEN Open
Conclusion | Biofuture2021
BIG EVENETS. Day 2 | Biofuture 2021
BIG EVENETS. Day 1 | Biofuture 2021
Wayne293™ Transient medium was launched